Literature DB >> 17865227

RESULTS OF THE INTRAVENOUS USE OF GENTIAN VIOLET IN CASES OF EXTREME SEPTICAEMIA.

D Hinton.   

Abstract

Entities:  

Year:  1925        PMID： 17865227      PMCID： PMC1399969          DOI： 10.1097/00000658-192503010-00015

Source DB:  PubMed          Journal:  Ann Surg        ISSN： 0003-4932            Impact factor:   12.969


× No keyword cloud information.
  7 in total

Review 1.  Novel antiangiogenic agents in dermatology.

Authors:  Ricardo L Berrios; Jack L Arbiser
Journal:  Arch Biochem Biophys       Date:  2010-12-21       Impact factor: 4.013

2.  PART II. CLINICAL RESULTS.

Authors: 
Journal:  Am J Public Health (N Y)       Date:  1926-10

3.  GENTIAN VIOLET IN RHEUMATIC CARDITIS.

Authors:  W Gunn
Journal:  Can Med Assoc J       Date:  1927-04       Impact factor: 8.262

Review 4.  Gentian violet: a 19th century drug re-emerges in the 21st century.

Authors:  Alexander M Maley; Jack L Arbiser
Journal:  Exp Dermatol       Date:  2013-12       Impact factor: 3.960

5.  Disruption of the mitochondrial thioredoxin system as a cell death mechanism of cationic triphenylmethanes.

Authors:  Xu Zhang; Yujuan Zheng; Levi E Fried; Yatao Du; Sergio J Montano; Allie Sohn; Benjamin Lefkove; Lars Holmgren; Jack L Arbiser; Arne Holmgren; Jun Lu
Journal:  Free Radic Biol Med       Date:  2011-01-04       Impact factor: 7.376

6.  Suppression of NF-κB activation by gentian violet promotes osteoblastogenesis and suppresses osteoclastogenesis.

Authors:  M Yamaguchi; T Vikulina; J L Arbiser; M N Weitzmann
Journal:  Curr Mol Med       Date:  2014       Impact factor: 2.222

7.  Gentian violet and ferric ammonium citrate disrupt Pseudomonas aeruginosa biofilms.

Authors:  Eric W Wang; Gabriela Agostini; Osarenoma Olomu; Daniel Runco; Jae Y Jung; Richard A Chole
Journal:  Laryngoscope       Date:  2008-11       Impact factor: 3.325
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.